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1. INTRODUCTION
High-altitude (HA) receives millions of visitors every 
year which include pilgrims, adventure seekers, tourists, and 
soldiers. Most of the visitors are unaware of the illnesses and 
adverse physiological changes associated with a rapid ascent 
to high-altitude. According to western literature, HA can be 
defined as altitude ranging from 1500 m to 3500 m. On the 
other hand, Indian literature defines HA as altitude ranging 
from 2438 m to 3658 m, ‘very high-altitude’ as altitude ranging 
from 3658 m to 5487 m, and ‘extremely high’ as altitude of 
5500 m and above as shown in Fig. 11- 4. 
Travelling to high-altitude areas lead to various kinds 
of high-altitude illness and it is becoming a pathological 
phenomenon about which healthcare management strategies 
are required. The main cause of high-altitude illness is hypoxia 
along with other stresses like cold and exertion. All these 
stresses are cumulatively responsible for the development 
and progression of various maladies like acute mountain 
sickness (AMS), high-altitude pulmonary edema (HAPE), 
high-altitude cerebral edema (HACE), high-altitude-induced 
thromboembolic disorders, etc. Unfortunately, high-altitude 
maladies are associated with morbidity and mortality 
significantly; therefore, there is a need for learning and 
recognizing early symptoms, prompt and timely therapy as 
well as proper preventive strategies by a medical specialist at 
high-altitude. 
The information about the susceptibility of the individuals 
going to HA is one of the prominent check point before 
finalizing ascent which is depending upon their past history 
of HA travelling, any pre-existing diseases, recent surgery and 
others. So, proper counselling of HA travellers is prerequisite 
by which adverse health conditions could be ignored5.  
This review focuses on thrombotic complications which 
are provoked at high-altitude and summarises the reported 
incidents, along with an overview of existing diagnostic and 
treatment strategies for thrombotic diseases. The present review 
may give wide scientific awareness for researchers working in 
the field of high-altitude medicine.
Thrombosis may be defined as a common medical 
condition that occurs due to the formation and propagation of a 
blood clot within the vasculature. It can occur either in arteries 
or veins. A blood clot formed in the deep veins especially in 
legs (Deep Vein Thrombosis DVT) may break off and travel 
up the veins through the heart and get lodged in the arteries 
of the lungs. This condition known as pulmonary embolism 
(PE) can be fatal when the size of the embolus is large 
(Fig. 2). People who lead a sedentary lifestyle are at a greater 
risk of developing DVT. DVT is also seen in people confined 
to bed for longer periods after surgeries and even travellers 
who take long-duration flights frequently. Thromboembolic 
disorders are a major cause of morbidity and mortality 
worldwide6. Several prothrombotic risk factors often work 
in a league to manifest clinical thrombosis. These include 
hereditary or acquired thrombophilia, immobility, surgical 
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trauma, inflammation, malignancy, estrogens and high-
altitude2. HA has been linked to a hypercoagulable 
state due to cold and hypoxic conditions. Several 
recent studies have shown an increased risk for 
cardiovascular diseases and thromboembolic 
events at HA7,8.
2.   INCIDENCE OF THROMbOEMbOLIC  
   DIsORDERs (TED) AT HA
Due to the lack of definitive epidemiological 
data, exact figures for incidences of TED at HA 
are unavailable. But previous reports do suggest a 
low incidence of TED in lowlanders at the plain as 
compared to at HA. Jha9, et al., observed that the cases 
of stroke in hospital admissions at HA were 13.7/1000 
and that in the plains was 1.05/1000. Kumar10, et al. 
studied the incidence of DVT in two hospitals serving 
military personnel (one at HA 3600 m and other at 
sea level). The relative risk for DVT at HA reported 
was 24.5 whereas; the lowland hospital received 2 
cases/year of DVT in a population of 70,000. In a 
retrospective study by Smallman11, et al., United States Air 
Force cadets stationed at an altitude of 2212 m were observed 
to have a twofold higher incidence rate of thromboembolic 
events than military personnel stationed at sea level. 
Dutta12, et al. described cases of PE among 53 Indian 
soldiers stationed at HA for up to 4 consecutive months. Only 
17 % of those soldiers had a hereditary thrombophilia and 
most of them had moved to HA from sea level. All available 
reports summarised in Table 1.
3. DIAGNOsIs OF VENOUs THROMbOsIs
Mortality and morbidity increase in venous 
thromboembolism due to the missed diagnosis in early 
phase13. Many conditions show similar signs and symptoms 
as VTE therefore early and accurate diagnosis of VTE is 
very important14. Despite non-specific symptoms, history 
and physical examination of patients are considered for the 
diagnostic process as they may provide an alternative cause for 
the symptoms which might be helpful in classifying patients 
for venous thrombosis15. Many tests have been evaluated over 
the years for diagnosing venous thrombosis16. D-dimer is one 
of them which denotes production of protein fragments when 
a blood clot gets dissolved in the body17. Usually it is not 
detectable at a very low level and it goes away with time but in 
case of a major clot D-Dimer level increases18. A D-dimer test 
is used to rule out the presence of a serious blood clot inside 
the body19. A negative D-dimer test means that the patient 
probably does not have a blood clot20. The D-dimer test often 
gives false-positive results in the case of malignancy, surgery 
or trauma, and pregnancy21. 
Another test for diagnosing VTE is venography in which 
uses a special type of radiographic material (dye) which is 
injected into the large vein in the foot so that the deep veins 
can be seen clearly22.  The contrast dye mixes with the blood 
and flows proximally so that the complete deep venous system 
of the leg, comprising the external iliac along with common 
iliac veins, can be imaged 23. It is considered as most accurate 
Figure 3. Diagnosis of venous thromboembolism in suspected 
patients.
Figure 1. High-altitude ranges in India and United states (Us): Changes 
in barometric pressure, association of oxygen levels with 
atmospheric pressure and clinical effects on exposure to high-
altitude to extreme high-altitude.
Figure 2. Illustration of deep vein thrombosis.
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test for diagnosing blood clots but it is invasive in nature24. 
Thus, it has been replaced by venous ultrasonography, which 
is readily available, painless, and can be performed easily 
without any painful procedure25,26. Venous ultrasonography 
uses sound waves to produce the images of veins in the body27. 
It is a standard imaging test as it can detect blockages in the 
deep veins28,29.
4. TREATMENT sTRATEGIEs: 
ANTICOAGULATION THERAPY 
Once VTE is diagnosed, treatment should be initiated, 
which either includes the usage of anticoagulants such 
as heparin, low molecular weight heparin or oral vitamin 
K antagonists to avoid additional clot enlargement30. 
Anticoagulants can be of two types like injectables and tablets 
such as heparin or low molecular weight heparin and warfarin, 
dabigatran, apixaban, rivaroxaban, edoxaban, respectively31. 
In certain cases, interventional procedures (like thrombectomy 
or the usage of inferior vena cava filters) and thrombolytic 
therapy may be used to breakdown the clot or may also be 
employed depending on the severity of the complication32.
5. LIMITATIONs OF CURRENT DIAGNOsTICs 
AND TREATMENT MODALITIEs 
Current diagnostics available for VTE have serious 
limitations, especially when considered with respect to 
availability at high-altitude. For example, plasma D-dimer 
levels can increase in many physiological and pathological 
conditions as in pregnancy, trauma, cancer, inflammation 
and several other clinical conditions; on the other hand, 
impaired fibrinolytic activity and use of oral anticoagulants 
prevent the increase in plasma D-dimer levels. D-dimer 
testing is also negative in case of onset of symptoms more 
than two weeks before blood sampling. High sensitivity and 
low specificity in the diagnosis of acute VTE is a significant 
clinical problem46.
Venography, as mentioned above, is the most accurate 
technique for diagnosing VTE but is an invasive procedure and 
venous ultrasonography, though non-invasive, is not as reliable 
for calf vein DVT, which has a significant risk of extending 
to PE. Also, both venography and venous ultrasonography 
are not readily available at HA, which can lead to further 
delay in accurately diagnosing VTE and thus delay in proper 
management and treatment, which in severe cases can lead to 
the death of the individual47.
Treatment followed by anticoagulant therapy (Table 2) is 
to be given such that the benefits outweigh the potential risks 
such as bleeding48. Unfractionated heparin poses an 8-10-fold 
higher risk for heparin-induced thrombocytopenia (HIT) than 
low molecular weight heparin. Although, fondaparinux has the 
specific benefit as it shows an extremely low incidence of HIT 
but it has numerous boundaries as an anticoagulant comprising 
its extended half-life (17–21 h with regular renal function) 
and absence of an antidote49 . Thus, the decisions regarding 
the choice of anticoagulant, its dosage and duration of the 
treatment are to be customised according to an individual’s 
needs with periodic monitoring and follow-ups.
6. FUTURE PERsPECTIVEs
In this review, an effort has been made to understand 
maladies associated with ascent to high-altitude when proper 
acclimatisation process is not followed. Limitations in available 
diagnostic and treatment regime obligate to continue research 
in altitude-related illness to reveal the exact underlying 
pathophysiology and the mechanism which will pave the way 
for developing specific and reliable diagnostic markers and 
therapeutics with a long-term perspective to improve the health 
and performance of every individual.
Table 1. Clinical cases of thromboembolic cases reported over the years
Publication year Description/ Title Ref. #
1983 Altitude-related deaths in seven trekkers in the Himalayas. [35]
1986 Cerebral venous thrombosis due to high-altitude polycythemia. [36]
1990 Chronic thrombosis of major pulmonary arteries. [37]
1999 Venous thromboembolism at high-altitude. [38]
2000 Portal system thrombosis: a new dimension of high-altitude illnesses. [39]
2002 Deep vein thrombosis at high-altitude. [40]
2002 Stroke at high-altitude: Indian experience. [9]
2003 A case of cerebral sinus thrombosis developed during a high-altitude expedition to Gasherbrum I. [41]
2005 Sinus vein thrombosis following exposure to simulated high-altitude. [42]
2006 High-altitude-induced deep venous thrombosis: a case study of 28 cases. [10]
2009 Cerebral venous infarction during a high-altitude expedition. [43]
2011 Quantification of the 5-year incidence of thromboembolic events in U.S. Air Force Academy cadets in 
comparison to the U.S. Naval and Military Academies.
[11]
2018 Profile of pulmonary embolism in service personnel posted at high-altitude area. [12]
2019 Cerebral Venous Thrombosis at High-altitude: A Retrospective Cohort of Twenty-one Consecutive Patients [44]
2019 Cerebral Venous Thrombosis at High-altitude: Analysis of 28 Cases. [45]
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Table 2. FDA approved anticoagulants and their mechanism of action33,34
Medicine Dosage Half-life Mode of dose Mechanism of action
Apixaban 10 mg twice daily for 7 days followed by 5 
mg twice daily
12 h Orally Direct factor Xa inhibitor
Edoxaban Adults <60 kg: 30 mg once daily, Adults >60 
kg: 60mg once daily for 21 days
10-14 h Orally Direct factor Xa inhibitor
Rivaroxaban 15 mg twice daily for 21 days, 5-9 h Orally Direct factor Xa inhibitor
Dabigatran 150 mg orally twice daily for 5- 10 days with 
a parenteral anticoagulant
12-17 h Orally Direct thrombin inhibitor
Betribaxan 160 mg on day 1, followed by 80 mg once 
daily for 35-42 days
19-27 h Orally Factor Xa inhibitor
Fondaparinux Adults < 50 kg: 5 mg once daily, Adults 50 to 
100 kg: 7.5 mg once daily
17-21 h Subcutaneously Indirect factor Xa inhibitor
Dalteparin 100 units per kg every 12 hours 3-5 h Subcutaneously Low-molecular-weight heparin
Enoxaparin 1 mg per kg every 12 hours 5-7 h Subcutaneously Low-molecular-weight heparin
Alteplase 100-mg over 2 hours 30-45 min Intravenous Fibrinolytics
Unfractionated heparin 8,000 to 10,000 units every 8 hours 1-5 h Subcutaneously Unfractionated heparin
Warfarin (Coumadin) 10 mg for the first 2 days with warfarin fol-
lowed by 5mg for more than a week
21-89 h Orally Vitamin K antagonist
REFERENCEs
1. Taylor, A.T. High-altitude illnesses: Physiology, risk 
factors, prevention, and treatment. Rambam Maimonides. 
Med. J., 2011, 2(1), e0022. 
 doi:10.5041/RMMJ.10022
2. Gupta, N. & Mohammad, Z. Ashraf. Exposure to high-
altitude: a risk factor for venous thromboembolism? Semin 
Thromb Hemost., 2012, 38 (2). 
 doi: 10.1055/s-0032-1301413
3. Gallagher, S.A. & Hackett, P.H. High-altitude illness. 
Emerg. Med. Clin. N. Am.,2004, 22, 329–355.
4. Selvamurthy, W. & Basu, C. High-altitude maladies: 
recent trends in medical management. Int. J. Biometeorol., 
1998, 42, 61–64. 
 doi: 10.1007/s004840050085
5. Schommer, K. & Bärtsch, P. Basic medical advice for 
travelers to high-altitudes. Dtsch. Arztebl. Int., 2011, 
108(49), 839-48. 
 doi: 10.3238/arztebl.2011.0839
6. Andrew, D. T.; Matthew, T. R.; David, A. K.Venous 
Thromboembolism at High-altitude: Our Approach to 
Patients at Risk. High. Alt. Med. Biol., Dec 2019.331-
336. 
 doi: 10 .1089/ham. 2019.0049
7. Whayne Jr, T.F. Cardiovascular medicine at high-altitude. 
Angiology, 2014, 65(6), 459-472. 
 doi: 10.1177/0003319713497086
8. Rong, Z.; Xiaochuan, Yu.; Yuanzhen, S.; Chunhui, Y.; 
Fengjuan, L.; Shengliang, Y.; Xi, D.; Li, M.; Haijun, 
C.; Zongkui, W. & Changqing, Li. Correlation between 
RBC changes and coagulation parameters in high-altitude 
population. Hematology, 2019, 24(1), 325-330. 
 doi: 10.1080/16078454.2019.1568658
9. Jha, S.K.; Anand, A.C.; Sharma, V.; Kumar, N. & Adya, 
C.M. Stroke at high-altitude: Indian experience. High. 
Alt. Med. Biol., 2002, 3(1), 21-27. 
 doi:10.1089/152702902753639513
10. Kumar, S. High-altitude induced deep venous 
thrombosis: A study of 28 cases. Indian. J. Surg., 2006, 
68(2), 84-88.
11. Smallman, D.P.; McBratney, C.M.; Olsen, C.H.; Slogic, 
K.M. & Henderson, C.J. Quantification of the 5-year 
incidence of thromboembolic events in U.S. Air Force 
Academy cadets in comparison to the U.S. Naval 
and Military Academies. Mil. Med., 2011, 176(2), 
209-213. 
 doi:10.7205/milmed-d-10-00144
12. Dutta, V.; Singh, R.; Kumar, S., Aggarwal, N. & 
Hari Kumar, K.V.S.Profile of pulmonary embolism 
in service personnel posted at high-altitude area. 
Indian Heart J., 2018, 70(3). 
 doi: 10.1016/j.ihj.2017.08.002
13. Essam, A.E.; Sharif, G. & Al-Hameed, F. Venous 
thromboembolism-related mortality and morbidity in 
King Fahd General Hospital, Jeddah, Kingdom of Saudi 
Arabia. Ann. Thorac. Med., 2011, 6(4),193-198. 
 doi:10.4103/1817-1737.84772
14. Bosevski, M. & Srbinovska-Kostovska, E. Venous 
Thromboembolism - Current Diagnostic and Treatment 
Modalities. Open Access Maced. J. Med. Sci., 2016, 4(3), 
523-525. 
 doi:10.3889/oamjms.2016.087
15. Abdulrahman, A.O.; Weina, Ju.; Dahui, S. & Baochang, 
Q. Deep venous thrombosis: a literature review. Int. J. 
Clin. Exp. Med., 2018, 11(3), 1551-61. 
16. Jonathan, S.; Patrick, H.; Hassan, A.; Alex, W.; Fadi, S.; 
228
KUMAR, et al.: DEF. LIFE SCI. J., VOL. 5, NO. 3, JULy 2020, DOI : 10.14429/dlsj.5.15490
Knuttien, M. G.; Sailendra, N. & Rahmi, O. Cardiovasc. 
Diagn. Ther., 2017, 7(Suppl 3), S276–S284. 
 doi: 10.21037/cdt.2017.09.01.
17. Tenna, A. M. S.; Kappadath, S. & Stansby, G. Diagnostic tests 
and strategies in venous thromboembolism. Phlebology, 
2012, 27(2_suppl), 43–52. 
 doi: 10.1258/phleb.2012.012s35
18. Chappell, F. M.; Andras, A.; Welch, K.; Di Nisio, M.; 
Robertson, L.; Stewart, M. & Crawford, F. D-Dimer 
tests for the diagnosis of deep venous thrombosis in 
symptomatic hospital outpatients with a clinical prediction 
rule. Cochrane Database Syst. Rev., 2016, 9, CD012356. 
 doi: 10.1002/14651858.CD012356.
19. Matsuo, H.; Nakajima, Y.; Ogawa, T.; Mo, M.; Tazaki, J.; 
Doi, T.; Yamada, N.; Suzuki, T. & Nakajima, H. Evaluation 
of D-Dimer in Screening Deep Vein Thrombosis in 
Hospitalized Japanese Patients with Acute Medical 
Diseases/Episodes. Ann. Vasc. Dis., 2016, 9(3), 193–200. 
 doi: 10.3400/avd.oa.16-00034
20. Nomura, H.; Wada, H.; Mizuno T.; Katayama, N.; Abe, 
Y.; Noda, M. & Sudo. Negative predictive value of 
D-dimer for diagnosis of venous thromboembolism. Int. 
J. Hematol., 2008, 87(3), 250-255. 
 doi:10.1007/s12185-008-0047-x
21. Sahakian, G. D.; Claessens, Y. E.; Allo, J. C.; Kansao, 
J.; Kierzek, G. & Pourriat, J. L. Accuracy of D-dimers 
to rule out venous thromboembolism events across age 
categories. Emerg. Med. Int., 2010.
 doi: 10.1155/2010/185453
22. de Valois, J.C.; van Schaik, C.C.; Verzijlbergen, F., van 
Ramshorst, B.; Eikelboom, B.C. & Meuwissen, O.J. 
Contrast venography: from gold standard to ‘golden 
backup’ in clinically suspected deep vein thrombosis. Eur. 
J. Radiol., 1990, 11(2), 131-137. 
 doi:10.1016/0720-048x(90)90162-5.
23. Karande, G. Y.; Hedgire, S. S.; Sanchez, Y.; Baliyan, 
V.; Mishra, V.; Ganguli, S. & Prabhakar, A. M. 
Advanced imaging in acute and chronic deep vein 
thrombosis. Cardiovasc Diagn Ther, 2016, 6(6), 493–
507. 
 doi: 10.21037/cdt.2016.12.06.
24. Theerakulpisut, D.; Wongsurawat, N. & Somboonporn, 
C. Detection of lower limb deep vein thrombosis: 
Comparison between radionuclide venography and venous 
ultrasonography. World J. Nucl. Med., 2018, 17(1), p. 27.
 
 doi: 10.4103/wjnm.WJNM_13_17
25. Kearon, C.; Ginsberg, J.S. & Hirsh, J. The role of venous 
ultrasonography in the diagnosis of suspected deep venous 
thrombosis and pulmonary embolism. Ann. Intern. Med, 
1998. 129(12), p. 1044-1049. 
 doi: 10.7326/0003-4819-129-12-199812150-00009
26. Lee, D.K.; Ahn, K.S.; Kang, C.H. & Cho, S.B. 
Ultrasonography of the lower extremity veins: anatomy 
and basic approach. Ultrasonography, 2017, 36(2), 120-
130. 
 doi: 10.14366/usg.17001
27. 27. Baroncini, L.A.; França, G.J.; Oliveira, A.D.; Vidal, 
E.A.; Del Valle, C.E.; Stahlke, P.S. & Faucz, R.  Correlation 
of  clinical  features  with  the  risk  of  lower  limb  deep 
vein  thrombosis  assessed  by  duplex  ultrasound.  J. 
Vasc.  Bras., 2013, 12(2), 118-22. 
 doi: 10.1590/S1677-54492013000200005
28. Katz, D.S.; Fruauff, K.; Kranz, A.O. and Hon, M. Imaging 
of deep venous thrombosis: A multimodality overview. 
Appl. Radiol., 2014, 43(3), 6-16.
29. Frederick, R.B.; Mark, C.D.; George, V.; Grace, R. & 
Fred, L.A. Venous thromboebolism: Venography in the 
Diagnosis of DVT. J. Trauma. Acute. Care. Surg., 2002, 
53,142-164.
30. McRae, S.J. & J.S. Ginsberg, Initial treatment of venous 
thromboembolism. Circulation, 2004, 110(9_suppl_1), 
I-3-I-9. 
 doi: 10.1161/01.CIR.0000140904.52752.0c
31. Palareti, G. and B. Cosmi, The direct oral anticoagulants 
may also be effective against the risk of post-thrombotic 
syndrome. Intern. Emerg. Med., 2019, -3. 
 doi: 10.1007/s11739-019-02251-9
32. Key, N.S. & R.S. Kasthuri. Current treatment of venous 
thromboembolism. Arterioscler. Thromb. Vasc. Biol., 
2010, 30(3), 372-375. 
 doi: 10.1161/ATVBAHA.109.197145
33. Wilbur, J. & B. Shian. Deep venous thrombosis and 
pulmonary embolism: current therapy. Am. Fam. Physician. 
2017, 95(5), 295-302. PMID: 28290648.
34. Hillis, C.M. & M.A. Crowthe. Acute phase treatment 
of VTE: Anticoagulation, including non-vitamin K 
antagonist oral anticoagulants. Thromb. Haemost., 2015, 
113(06), 1193-1202. doi: 10.1160/TH14-12-1036.
35. Dickinson, J.; Heath, D.; Gosney, J. & Williams, 
D. Altitude-related deaths in seven trekkers in the 
Himalayas. Thorax., 1983, 38(9), 646-656. doi: 10.1136/
thx.38.9.646.
36. Fujimaki, T.; Matsutani, M.; Asai, A.; Kohno, T. & Koike, 
M. Cerebral venous thrombosis due to high-altitude 
polycythemia. Case report. J. Neurosurg., 1986, 64(1), 
148-150. 
 doi: 10.3171/jns.1986.64.1.0148
37. Presti, B.; Berthrong, M. & Sherwin, R.M. Chronic 
thrombosis of major pulmonary arteries. Hum Pathol., 
1990, 21(6), 601-606. 
 doi: 10.1016/s0046-8177(96)90005-2
38. Bucur, I.J. Venous thrombo-embolism at high-altitude. 
Saudi Med. J., 1999, 20(5), 351. PMID: 27631284
39. Anand, A.C.; Saha, A.; Kumar, R.; Sharma, V. & Jha, 
S.K. Portal system thrombosis: a new dimension of high-
altitude illnesses. Trop. Gastroenterol., 2000, 21(4), 172-
173. PMID: 11194576
40. Hussain, T. & Niaz, A. Deep vein thrombosis at high-
altitude. J. Pak. Med. Assoc., 2002, 52(9), 440. PMID: 
12532586
41. Saito, S. & Tanaka, S.K. A case of cerebral sinus 
thrombosis developed during a high-altitude expedition 




KUMAR, et al.: DEF. LIFE SCI. J., VOL. 5, NO. 3, JULy 2020, DOI : 10.14429/dlsj.5.15490
42. Torgovicky, R.; Azaria, B.; Grossman, A.; Eliyahu, U. & 
Goldstein, L. Sinus vein thrombosis following exposure 
to simulated high-altitude. Aviat. Space. Environ. Med., 
2005, 76(2), 144-146. PMID: 15742833
43. Cheng, S.; Chng, S.M. & Singh, R. Cerebral venous 
infarction during a high-altitude expedition. Singapore 
Med J., 2009, 50(8), e306-e308.PMID: 19710966
44. Khattar, N.K.; Sumardi, F, Zemmar A, Liang, Q.; Li, 
H.; Xing, Y.,;Andrade-Barazarte, H.; Fleming, J. L.; 
Cherian, I.; Hernesniemi, J.; Neimat, J. S.; James, R. F.; 
Munakomi, S. & Ding, D. al. Cerebral Venous Thrombosis 
at High-altitude: A Retrospective Cohort of Twenty-one 
Consecutive Patients. Cureus., 2019, 11(6), e4940.
 doi:10.7759/cureus.4940
45. Hassan, W.U.; Syed, M.J.; Alamgir, W.; Awan, S.; Bell, S. 
M.; Majid, A. & Wasay, M. Venous Thrombosis at High-
altitude: Analysis of 28 Cases. Cerebrovasc. Dis., 2019, 
48 (3-6), 84-192. 
 doi:10.1159/000504504
46. Imberti, D. D-dimer testing: advantages and limitations 
in emergency medicine for managing acute venous 
thromboembolism. Intern. Emerg. Med., 2007, 2(1), 70-
71. 
 doi: 10.1007/s11739-007-0020-3
47. National Clinical Guideline Centre. Venous 
thromboembolic diseases: The management of venous 
thromboembolic diseases and the role of thrombophilia 
testing. London: Royal College of Physicians (UK), 2012. 
PMID: 23638495/ NBK132796
48. Nutescu, E.A.; Burnett, A.; Fanikos, J.; Spinler, S. & 
Wittkowsky, A. Erratum to: Pharmacology of anticoagulants 
used in the treatment of venous thromboembolism. J. 
Thromb. Thrombolysis., 2016, 42(2), 296-311. 
 doi: 10.1007/s11239-016-1363-2
49. Streiff, M.B.; Agnelli, G.; Connors, J.M.; Crowther, M.; 
Eichinger, S.; Lopes, R.; McBane, R.D.; Moll, S. & Ansell, 
J. Guidance for the treatment of deep vein thrombosis and 





Mr Vinay Kumar is currently working as Senior Research 
Fellow at DRDO-Defence Institute of Physiology and Allied 
Sciences, Delhi. His current area of research involves 
understanding of pathophysiology of deep venous thrombosis at 
high-altitude. 
Contribution in the current study: literature search and 
writing. 
 
Mr Chhavi Rai is currently working as Senior Technical Assistant 
‘B’ at DRDO-Defence Institute of Physiology & Allied Sciences, 
Delhi. She has been working to understand the pathophysiology 
of high-altitude induced venous thromboembolism. 
Contribution in the current study: literature search and 
writing. 
Dr swati srivastava did Masters and PhD from University of 
Delhi. She is presently serving as Scientist in Genomics Group 
at DRDO-Defence Institute of Physiology & Allied Sciences, 
Delhi. Her research interests zinclude identification of biomarkers 
for susceptibility and genetic resistance of human beings to 
various high-altitude maladies such as venous thrombosis and 
HAPE under extreme environmental conditions. 
Contribution in the current study: Monitoring and editing.
 
Dr bhuvnesh Kumar, obtained his Post graduate and Doctorate 
degrees in Veterinary Medicine from G.B. Pant University of 
Agriculture and Technology, Pantnagar, Uttarakhand. He is 
a Scientist ‘H (Outstanding)’ and Director, DRDO-Defence 
Institute of Physiology & Allied Sciences, Delhi. His focus 
is on rapid induction and acclimatisation to high-altitude and 
enhancing combat efficiency of soldier in stressful environmental 
conditions through physiological, biochemical, nutritional and 
ergonomical approaches. 
Contribution in the current study: overall monitoring and 
guidance during manuscript preparation.
 
Dr Iti Garg received her PhD (Biochemistry) from Central 
Drug Research Institute (CDRI-CSIR), Lucknow. Currently, she 
is working as Scientist ‘E’, Group Head, Genomics division 
at DRDO-Defence Institute of Physiology & Allied Sciences, 
Delhi and has over 35 publications in  journals to her credit. 
Her research mainly covers understanding of pathophysiology 
of thrombotic disorders induced by high-altitude exposure to 
Indian Army Soldiers by various approaches. 
Contribution in the current study: Designing and conceptualisation 
of manuscript, overall monitoring and editing.
